



Neobiomics AB and Gennisium Pharma announce an exclusive collaboration for distribution of ProPreams® in France

Stockholm October 12, 2021 - Neobiomics and Gennisium Pharma have entered into a Distribution Agreement under which Gennisium has the exclusive rights to register, market and sell Neobiomics' proprietary product ProPreams® in France, in effect immediately.

ProPreams® is a high-quality product for safe food supplementation with one billion bacteria of three well-documented strains - *Bifidobacterium infantis*, *Bifidobacterium lactis* and *Streptococcus thermophilus*.

Dr. Stefan Johansson, CEO and co-founder of Neobiomics AB, says: "We are very happy to extend our distributor network by cooperating with Gennisium. Gennisium is a perfect partner for us, with capacity to make ProPreams® readily available in France."

Franck Pigache, CEO and co-founder of Gennisium, comments: "We are delighted to work with Neobiomics, an innovative company with an R&D pipeline of products within neonatal intensive care, just like Gennisium. This partnership represents a significant addition to our portfolio in France and fits with our strategy to build a strong and niched business."

About Neobiomics

Neobiomics AB was founded in 2016 by Stefan Johansson and Philipp Novak to solve unmet needs in pediatric health care, initially embedded in the Incubator of the Karolinska Institutet Innovation AB. The first product ProPreams® is used in many hospitals in Europe.

About Gennisium Pharma

Gennisium is a French pharmaceutical company with global reach, set up in 2018 and specialized in development and commercialization of products within neonatology. Its mission is to provide health care practitioners and neonatal intensive care units with novel and suitable formulations of medicines.

For further information, please contact:

Neobiomics AB
Stefan Johansson
co-founder & CEO
info@neobiomics.eu

Gennisium Pharma
Frank Pigache
co-founder & CEO
fpigache@gennisium.com